CRISPR Therapeutics granted FDA RMAT for CTX110 for CD19+ B-cell cancers

By The Science Advisory Board staff writers

November 29, 2021 -- CRISPR Therapeutics received the U.S. Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation for CTX110, an allogeneic CAR T-cell therapy, for the treatment of relapsed or refractory CD19+ B-cell malignancies.

CTX110 is a donor-derived, gene-edited, allogeneic CAR T investigational therapy that targets B-lymphocyte antigen CD19. It is the subject of the ongoing CARBON clinical trial, a phase I, single-arm, multicenter, open-label clinical trial designed to assess safety and efficacy, according to the company.

The RMAT designation expedites the drug development and review processes for promising cell therapies that are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition that has unmet medical or therapeutic need. Similar to the FDA's Breakthrough Therapy designation, the RMAT designation provides the benefits of intensive FDA guidance on efficient drug development, potential accelerated approval and post-approval requirements, as well as potential priority review of the biologics license application.

CRISPR Therapeutics develops genetically engineered therapies for serious diseases in the fields of hemoglobinopathies, oncology, regenerative medicine, and rare diseases, using its proprietary CRISPR-Cas9 gene-editing platform. CRISPR Therapeutics has partnerships with Bayer, Vertex Pharmaceuticals, and ViaCyte, according to CRSPR Therapeutics. CRISPR Therapeutics' headquarters is in Zug, Switzerland, with its U.S. subsidiary and R&D operations based in Cambridge, MA.

CRISPR Therapeutics, Nkarta partner on gene edited cancer therapies
CRISPR Therapeutics has established a strategic partnership with Nkarta to research, develop, and commercialize CRISPR/Cas9 gene edited cell therapies...
Vertex, CRISPR Therapeutics ink deal on sickle cell gene therapy
Vertex Pharmaceuticals and CRISPR Therapeutics have amended their collaboration agreement to develop, manufacture, and commercialize CTX001, an ex vivo...
Lineage improves manufacturing of allogenic cell therapy product
Lineage Cell Therapeutics has provided an update for its OPC1 cell therapy program, an oligodendrocyte progenitor cell transplant for the treatment of...
Regulatory Roundup: antibodies, immunotherapies, expanded flu treatment use
Welcome to this week's edition of Regulatory Roundup. This past week, several novel therapies for the treatment of rare diseases and cancers have received...
Regulatory Roundup: Gene therapies, bispecific antibodies lead new approvals
Welcome to Regulatory Roundup, a new Science Advisory Board feature that tracks recent regulatory activities in the life sciences industry. Recent approvals...

Copyright © 2021

Cell Bio 2022
December 3-7
District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter